Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 19/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 6/20 | 0.60 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.60 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.60 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924749 | 0.85 | DHODH (0.72) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL3924512 | 0.84 | DHODH (0.72) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL246019 | 0.82 | DHODH (0.59) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL252550 | 0.81 | DHODH (0.73) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL252180 | 0.80 | DHODH (0.72) | DHODHNR4A2NPSR1 | |
| SCHEMBL3915685 | 0.80 | DHODH (0.60) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL3926132 | 0.78 | DHODH (0.61) | DHODHNR4A2NPSR1 | |
| SCHEMBL3925167 | 0.77 | DHODH (1.00) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL249278 | 0.77 | DHODH (0.69) | DHODHNR4A2JMJD7NR4A1NR4A3 | |
| SCHEMBL3914884 | 0.77 | DHODH (0.78) | DHODHNR4A2JMJD7NR4A1NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | SERVIER PHARMACEUTICALS LLC | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190025313-A1 | TREATMENT OF TUMORS INCORPORATING MUTANT ISOCITRATE DEHYDROGENASE | DHODH, IDH1, IDH3A | DHODH 1/4885NR4A2 3748/4885JMJD7 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.